ArticleVirology journal2025
Molecular epidemiology, coinfection, and diversity of enteroviruses detected in respiratory samples collected from patients with influenza-like illness in Hangzhou, China, in 2023.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The coronavirus pandemic in China ended in 2022, and stringent control measures were lifted in 2023. This study investigated the pathogen and endemic characteristics of enteroviruses (EVs) in patients with influenza-like illness (ILI) in Hangzhou, China, in 2023, providing a foundation for the prevention and control of EV infections. Throughout 2023, 3,480 throat swab samples were collected from hospitals across Hangzhou. Among these, 130 were positive for EVs, with a positivity rate of 3.74%. Successful sequencing and typing were achieved for 91 cases (70.00%, 91/130), which included four enterovirus A (EV-A), three enterovirus B (EV-B), and one enterovirus D (EV-D) species. EV-A was predominant in 94.51% (86/91) of the samples, followed by EV-B (4.40%, 4/91) and EV-D (1.10%, 1/91). Notably, coxsackievirus A6 was the dominant genotype detected, accounting for 60.44% (55/91) of the samples. Coinfection with 12 distinct non-EV respiratory pathogens was also observed in a significant proportion (75.82%, 69/91) of the samples. Summer and autumn represented peak periods for EV circulation, and children < 8 years of age constituted the primary demographic group affected. There were no sex-based differences in the positivity rate of EV detection (χ²=0.258, P = 0.655). Phylogenetic analyses based on partial VP1 sequences revealed that each representative strain clustered with its corresponding reference strain. Isolated CV-A4 strains were classified within subgenotype C2, CV-A6 strains within subgenotype D3, and CV-A10 strains within subgenotype C1. In conclusion, EV infections among ILI cases in Hangzhou during 2023 peaked in summer and autumn (July and October), with CV-A6 emerging as the predominant type. Children aged 0-7 years constituted the primary risk group for EV infection, with no significant sex-based differences observed. Incorporating EV screening into influenza sentinel surveillance would enhance understanding of endemic trends and pathogen characteristics in ILI patients, thereby informing evidence-based prevention policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.